Behind The Latest Breast Cancer Research


"The impact is tremendous", said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in NY.

The results suggest that these women can undergo hormone therapy alone instead of hormone therapy and chemotherapy? The team at the US National Cancer Institute says that the treatment is still experimental and new, but possibly will transform the dealing of all cancer. Results were discussed Sunday at an American Society of Clinical Oncology conference in Chicago and published by the New England Journal of Medicine.

About 17 percent of women had high-risk scores and were advised to have chemo. The recurrence rate was 3 percent after nine years for the women in the low-risk group who had received only hormone therapy.

Women with cancer receive scores based on genetic tests that determine the likelihood of relapse.

The same decade-long study had previously confirmed that patients at low risk, as determined by a genomic test of their tumors, can skip chemotherapy.

"There's always been this big grey zone", he said. "We were upset, because we didn't know what to tell them, and then the patient would get upset".

"We need a new paradigm for cancer therapy", he says.

Blaes said gene expression profiles for tumors can help customize care for individual patients. Similar tests including one called MammaPrint also are widely used. When all those methods failed to halt the spread of cancer to her chest and liver, she was sure she was going to die - that is, until she met Dr. Steven Rosenberg at the National Institutes of Health.

Dr. Lisa Carey, a breast specialist at the University of North Carolina's Lineberger Comprehensive Cancer Center, said she would be very comfortable advising patients to skip chemo if they were like those in the study who did not benefit from it.

"I think it's been well spent", Singer said of the stamp proceeds. Rosenberg is a pioneer in harnessing the immune system to fight cancer.

Del Potro powers past Cilic to set up Rafa clash
Two women who have won the title at Roland Garros, Maria Sharapova and Garbine Muguruza, play each other in the quarterfinals. Schwartzman took a set from Nadal, but a weather delay recharged Nadal and he stormed back to take the next three sets.

At Mosaic Life Care, we have been using this personalized approach for five years and the study results were a confirmation of our treatment guidelines.

Staff writer Elizabeth Fite contributed to this story. That means more than 85,000 women a year can safely forgo chemotherapy.

"I was a little relieved". Perkins said she "cornered her with a beer" and said she wanted to enroll.

Melinda Bachini, a former paramedic who lives in Billings, Montana, believes the treatment saved her life.

"The idea behind the trial is to use two drugs to try and increase the immune response in the tumor and then start the chemotherapy", Dr. Bear said.

Because she wasn't high risk, doctors thought that was her best option. "I'm a firm believer in medical research".

This shows that adding or removing chemotherapy does not have much influence if the disease could diagnose at early-stage.

The usual treatment is surgery followed by years of a hormone-blocking drug. "If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers". "But we need to be precise on when to use it and who to recommend it to".

Experimental therapy is that the patient's body are transplanted 90 billion immune cells that kill cancer.

"It's one of the first studies we've ever had".